CEACAM5 and metastatic colorectal cancer: (55) conducted Ad5 [E1-,E2b-]-CEA (6D) to enhance CEA-specific T cell-mediated immune response and proved its safety and efficacy in 32 metastatic colorectal cancer (mCRC) patients recruited to a phase I/II trial with OS of 48% at 12 months.